Pharmaceutical company Eli Lilly has opened a valid means of slowing the development of Alzheimer's disease. The results of recent clinical trials will be published on the day.
Solanezumab may be one of the first tools that are able to delay critical violations in the nervous system in Alzheimer's disease. Note, the drug is not marketed as a "vaccine", coping with illness, he repels her consequences.
While doctors are the drugs that have minimal effectiveness, is able to attenuate the symptoms of the disease. If solanezumab pass all required tests, the medicine will get a really effective tool against Alzheimer's disease.
Previously, the pharmaceutical giant Biogen Idec Inc has published information on the development of experimental tools, which gives a chance to people with Alzheimer's disease to improve their condition.